Following the decision of the Scientific Technical Committee (CTS) that standardised the prescription criteria for antiviral medicines (remdesivir, nirmatrelvir/ritonavir and molnupiravir) and anti-SARS-CoV-2 monoclonal antibodies, as they are directed to the same population group represented by individuals with mild/moderate COVID-19 disease and high risk of developing severe disease, the Agency makes available the new therapeutic plan for the prescription of Paxlovid (in 'Related documents').

The computerized prescribing systems (web-based TP for the prescription of nirmatrelvir/ritonavir by the general practitioner and AIFA monitoring registers for the prescription of remdesivir, molnupiravir and monoclonal antibodies by the centres identified by the Regions) have been implemented with the appropriate modifications and are operational as of 24 May 2022.